Patel Zarana S, Yamamoto Masaya, Ueda Hiroki, Tabata Yasuhiko, Mikos Antonios G
Department of Bioengineering, Rice University, P.O. Box 1892, MS-142, Houston, TX 77251-1892, United States.
Acta Biomater. 2008 Sep;4(5):1126-38. doi: 10.1016/j.actbio.2008.04.002. Epub 2008 Apr 22.
This work evaluated gelatin microparticles and biodegradable composite scaffolds for the controlled release of bone morphogenetic protein-2 (BMP-2) in vitro and in vivo. Gelatin crosslinking (10 and 40mM glutaraldehyde), BMP-2 dose (6 and 60ng BMP-2 per mg dry microparticles), buffer type (phosphate buffered saline (PBS) and collagenase-containing PBS), and gelatin type (acidic and basic) were investigated for their effects on BMP-2 release. Release profiles were also observed using poly(lactic-co-glycolic acid) (PLGA) microparticles with varying molecular weights (8300 and 57,500). In vitro and in vivo studies were conducted using radiolabeled BMP-2; the chloramine-T method was preferred over Bolton-Hunter reagent for radioiodination with this system. BMP-2 release from PLGA microparticles resulted in a moderate burst release followed by minimal cumulative release, while BMP-2 release from gelatin microparticles exhibited minimal burst release followed by linear release kinetics in vitro. Growth factor dose had a small effect on its normalized release kinetics probably because of an equilibrium between gelatin-bound and unbound BMP-2. Differences in release from acidic and basic gelatin microparticles may result from the different pretreatment conditions used for gelatin synthesis. The in vitro release kinetics for both gelatin microparticles alone and within composite scaffolds were dependent largely on the extent of gelatin crosslinking; varying buffer type served to confirm that controlled release relies on enzymatic degradation of the gelatin for controlled release. Finally, in vivo studies with composite scaffolds exhibited minimal burst and linear release up to 28 days. In summary, dose effects on BMP-2 release were found to be minimal while varying gelatin type and release medium can alter release kinetics. These results demonstrate that a systematic control of BMP-2 delivery from gelatin microparticles can be achieved by altering the extent of basic gelatin crosslinking.
本研究评估了明胶微粒和可生物降解复合支架在体外和体内对骨形态发生蛋白-2(BMP-2)的控释性能。研究了明胶交联(10和40mM戊二醛)、BMP-2剂量(每毫克干微粒6和60ng BMP-2)、缓冲液类型(磷酸盐缓冲盐水(PBS)和含胶原酶的PBS)以及明胶类型(酸性和碱性)对BMP-2释放的影响。还使用了不同分子量(8300和57,500)的聚(乳酸-共-乙醇酸)(PLGA)微粒观察释放曲线。使用放射性标记的BMP-2进行体外和体内研究;在该系统中,氯胺-T法比博尔顿-亨特试剂更适合用于放射性碘化。PLGA微粒释放BMP-2会导致适度的突释,随后累积释放量极小,而明胶微粒释放BMP-2在体外表现出极小的突释,随后是线性释放动力学。生长因子剂量对其标准化释放动力学影响较小,可能是因为明胶结合的和未结合的BMP-2之间存在平衡。酸性和碱性明胶微粒释放的差异可能源于明胶合成所用的不同预处理条件。单独的明胶微粒以及复合支架内的明胶微粒的体外释放动力学在很大程度上取决于明胶交联的程度;改变缓冲液类型有助于证实控释依赖于明胶的酶促降解以实现控释。最后,复合支架的体内研究显示在长达28天的时间内突释极小且呈线性释放。总之,发现剂量对BMP-2释放的影响极小,而改变明胶类型和释放介质可改变释放动力学。这些结果表明,通过改变碱性明胶交联程度可以实现对明胶微粒中BMP-2递送的系统控制。